User:Lmmartinez420/Drug policy of California

Article body
User:Morganhelm/Drug_policy_of_California

Psilocybin (mushrooms)

Psilocybin itself still categorized as a Schedule I Controlled Substance according to the United States Drug Enforcement Administration under federal law. Schedule I drugs are identified as those with the highest potential for substance abuse, and has chemical properties that enables addictive behavior. Under California Law, possession of Psilocybin Mushrooms can result in a range of penalties varying from a $1,000 fine, mandatory community service, or potentially serving one year in county jail. Whereas distributing a Schedule I Controlled Substance such as psilocybin is recorded as a felony, with the potential to serve in a jail or state prison. In California, the Controlled Substances Act of 1970 still prohibits any use or possession of psilocybin, or any other psychedelics.

Following World War II, a new social movement referred to as "Psychedelic Culture" became increasingly popular amongst young adults. As the Psychedelic Culture movement rapidly grew, concerns for increased drug use became a national issue, which led to the implementation of The Controlled Substances Act of 1970

However, on February 17, 2021, Senator Scott Wiener proposed Senate Bill-519 which would overturn all previous legal consequences towards psychedelics. Senate Bill-519 gained approval on June 29, 2021 on the terms that Ketamine would be redacted from the original proposal. Senate Bill-519was approved with a 5-3 vote from the Assembly Public Safety Committee for their advocacy towards the use of furthering scientific research behind psychedelic therapy treatment. Psilocybin has been in the process of undergoing clinical trials as mental health professionals and scientists gather data demonstrating the drugs potential benefits. Upon approval from the Drug Enforcement Administration, psilocybin have both been used in clinical trials in attempts to study the medicinal purposes. University of California, San Francisco has invested in clinical trials of psilocybin as part of a treatment to mental health diagnoses such as Bipolar II Disorder as well as Depression. In September of 2020, there have been over 1,000 reported clinical trials of Psilocybin therapy research conducted for various diagnoses and have even produced evidence to show that the psychotherapy approach demonstrates prolonged antidepressant effects.